Low-dose aspirin use and risk of head and neck cancer - A Danish nationwide case-control study

Head and Neck Cancer

Br J Clin Pharmacol. 2020 Jul 31. doi: 10.1111/bcp.14502. Online ahead of print.


Results concerning a potential preventive effect of aspirin on head and neck cancer (HNC) are conflicting. We examined the association between low-dose aspirin use and HNC risk overall and by degree of human papillomavirus (HPV) association in a nested case-control study using nationwide registries. Cases (n=12,389) were all Danish residents diagnosed with primary HNC (2000-2015). Age- and sex-matched population controls (n=185,835) were selected by risk-set-sampling. Using conditional logistic

regression, we estimated multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for HNC associated with low-dose aspirin use (≥2 prescriptions). No association was observed between low-dose aspirin ever-use and overall HNC (OR: 1.03, 95% CI: 0.97-1.10). Estimates remained neutral according to patterns of use. Low-dose aspirin use appeared to slightly decrease HNC risk among the eldest (71-84 years), independently of HPV-association, while slightly increase HNC risk among younger age groups (30-60, 61-70 years), driven by an increased risk of oral cancer. However, no consistent patterns in risk estimates were found according to duration and consistency of low-dose aspirin use in the age-stratified analyses.